<DOC>
	<DOC>NCT00574873</DOC>
	<brief_summary>Two-arm, randomized, open-label trial designed to evaluate the efficacy and safety of bosutinib alone compared to imatinib alone in subjects newly diagnosed with chronic phase Chronic Myelogenous Leukemia (CML). The primary endpoint is cytogenetic response rate at one year.</brief_summary>
	<brief_title>Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Cytogenetic diagnosis of chronic phase Ph+ CML diagnosed less than 6 months. Diagnosis of CML chronic phase confirmed. Adequate hepatic and renal function. Able to take oral tablets. Exclusions include Philadelphia negative CML. Prior antileukemia treatment. Prior stem cell transplant.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Bosutinib</keyword>
	<keyword>imatinib</keyword>
	<keyword>CML</keyword>
</DOC>